Browse the search results

Identification and exploitation of interactions between the antifungal drug fluconazole and FDA- approved drugs has the potential to improve treatment for patients with difficult-to-treat systemic fungal infections.

A study that models the evolution of drug resistance in tumors reveals that drugs are more effective when given in combination than sequentially, and that cure is much more likely when the drugs target different pathways.

Dalpiciclib could partially abrogate ER nuclear transportation induced by pyrotinib in HER2+HR+ breast cancer and CALML5 could serve as a potential risk factor in the treatment of HER2+HR+ breast cancer.

Combined EGFR and SOS1 inhibition synergize to inhibit NSCLC spheroid growth.

The immune Synergistic/Antagonistic Interaction Learner (iSAIL) resource has the capacity to generate insight into combinatorial immunity, help guide hypothesis generation and further experimentation relevant to basic research and drug therapeutics.

Fibrolamellar carcinoma results from a genetic lesion that produces the DNAJ-PKAc fusion kinase, which is recruited into macromolecular complexes and is sensitive to combinations of signal transduction inhibitor drugs.

A simple mathematical model reveals that antibiotic interactions and collateral effects of evolution are inseparable drivers of multidrug resistance linked by the well-known Price equation from evolutionary theory.

The oral carbapenem 'Tebipenem' has high level antibacterial activity against highly drug-resistant Shigella, and its mode of action and pharmacokinetics make it suitable for the treatment of severe diarrhoea caused by highly drug-resistant bacteria.

Nearly a thousand diverse adaptive mutants converge into a handful of groups for which fitness responds the same way to environmental change.

Overlaying single cell readouts of cell cycle and apoptosis onto a multidimensional analysis of pulsed cisplatin signalling dynamics reveals targetable mechanisms of platinum resistance in lung adenocarcinoma.